Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
about
Advances in development of fluorescent probes for detecting amyloid-β aggregatesAlzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkersGenetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunitiesDiagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysisCerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques.Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.Correlation between two methods of florbetapir PET quantitative analysis.The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging.Molecular imaging of Alzheimer disease pathologyThe Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using (18)F-AV45: Is Amyloid the Principal Actor in the Disease?A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysisUse of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral AmyloidosisPreliminary Characterization and In Vivo Studies of Structurally Identical (18)F- and (125)I-Labeled Benzyloxybenzenes for PET/SPECT Imaging of β-Amyloid Plaques.The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regressionQuantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages.Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Recent advances in neuroimaging biomarkers in geriatric psychiatry.Discovery of a novel fluorescent probe for the sensitive detection of β-amyloid deposits.A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease.Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects.Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Amyloid-β probes: Review of structure-activity and brain-kinetics relationships.Current status of PET-imaging probes of β-amyloid plaques.Amyloid imaging in Alzheimer's disease: a literature review.A new integrated dual time-point amyloid PET/MRI data analysis method.Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.PiB-Conjugated, Metal-Based Imaging Probes: Multimodal Approaches for the Visualization of β-Amyloid Plaques.Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study.An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.Interaction of PiB-derivative metal complexes with beta-amyloid peptides: selective recognition of the aggregated forms.
P2860
Q26753175-CBD89461-DB2F-42EF-9AFF-749C428404F6Q26825442-688CEB2C-D0D9-4368-98A6-3C1FA02CED60Q28086879-8A37D5B4-954C-45B6-94E9-A7FFD6B2C439Q28088506-C28DA824-2B0F-4888-BD47-CE32DC49D996Q30275833-94E9B3D4-4DCF-4C59-975E-E8CD556904A0Q30706028-68145AD9-CCE6-408A-B12C-B5FB368A2CB1Q31028845-9E2D7571-3EB7-44F1-9C09-B6BF32903101Q31096423-F4E2E56F-8582-465E-BC18-0B57792CBE41Q33701135-30F37C60-B5B8-48FA-94A4-B0627F64E247Q33905494-8C1B4928-F557-41D5-9A92-7824D90D8715Q34296479-50A1962E-15B9-4BDE-BFBE-D18B701B969EQ34651135-589FB1DC-C539-4C47-851C-FD61546FCFC9Q34687210-DD7EFABE-4042-4051-A0A8-A2AACD520A79Q35158547-EC1CB9F4-DCD7-4559-A9FE-CDC87496BE50Q35576440-1A670FDF-4FB2-4D5D-AFF2-4C9B475AB9BDQ35639988-765002E2-3D7E-4DBA-828C-04E906841A84Q35847954-DA480684-FC3F-4B41-9A54-920D2FD4B063Q35864927-D7391D7D-5FD2-46E5-A109-CE5F50A44D98Q36267484-A03DA870-002A-4E46-A4A4-BC11A84B4943Q36348208-03837834-7AEB-4C0F-88EB-EF3EEB01FB16Q36526176-77E81A99-FB32-4219-826D-09A6D5F8611DQ36885496-B0AC9AFF-E2C4-4765-A4ED-0CC692D295F1Q36920551-5702DE1B-C2FD-4A36-8015-249DF61E164FQ36926707-708A5508-7D08-4464-85D8-7CB5EEF528EDQ37402288-8CF7414A-EA83-4C47-98A9-57D5DE012A96Q37689338-A03A540F-E64A-40D9-BE0A-FFE5AC615C75Q37714491-F1A585E5-9D4B-4E94-9204-7CAB4E82A1AEQ37718557-958F1CB0-81DB-40E2-91DE-73F29FDA6989Q38114434-5DD251B6-13F5-4D39-9B91-DC02B34CB90DQ38118149-E554C3C1-C422-4681-B8AB-8589AE358478Q38250091-3799F3E8-01AF-46E4-B71F-B4D54D9A4C8BQ38694948-721D9209-5C31-4C5B-B8B2-988713B6549EQ38888294-7799E06F-4C9F-41D7-87F8-618CF1AA759DQ38979999-B86E3EBF-8B48-4C28-BCD1-1F6CB4ABF2F7Q39219904-032B8C3A-F951-47E9-B4DE-1F6E7CC05EAEQ39780926-4C0C659C-A0FD-4E24-985E-9DE7C3CD1645Q39962773-840F8334-7072-467C-B99F-120613DF363EQ40485355-82EA4631-2289-4044-9159-B7E7EF747D47Q41072137-207141D3-15FF-4B6D-8477-AEA13E37DE4AQ41356279-64A14FC6-21A3-4C7C-8DCB-9107DE5362A5
P2860
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@ast
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@en
type
label
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@ast
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@en
prefLabel
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@ast
Using PET with 18F-AV-45 (flor ...... oad in a clinical environment.
@en
P2093
P2860
P50
P1476
Using PET with 18F-AV-45 (flor ...... load in a clinical environment
@en
P2093
D Guilloteau
G Chételat
M J Ribeiro
P2860
P2888
P304
P356
10.1007/S00259-011-2021-8
P50
P577
2012-01-18T00:00:00Z